Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the champion gene-editing stocks to bargain according to hedge funds. On November 11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and chopped its terms people to $8 from $17, citing uncertainty astir the company’s ATTR programme timeline. While acknowledging promising efficacy updates, the steadfast noted that clarity connected improvement milestones remains lacking, narrowing the way to value.

Source: Pexels

The downgrade followed Intellia’s November 10 announcement of three‑year follow‑up information from its Phase 1 proceedings of nexiguran ziclumeran (nex‑z) successful transthyretin (ATTR) amyloidosis with cardiomyopathy. Results showed an 87% mean serum TTR simplification astatine 36 months with nary waning effect, alongside stabilization oregon betterment successful cardinal biomarkers and functional status. Mortality rates were besides importantly little compared to a matched cohort, underscoring the therapy’s imaginable impact.

CEO John Leonard highlighted the durability of payment adjacent successful precocious bosom nonaccomplishment patients, calling the results “remarkable.” Reported adverse events were constricted to mild infusion reactions and transaminase elevations. Intellia is moving to resoluteness an FDA objective clasp connected its Phase 3 MAGNITUDE trials, which stay captious for advancing nex‑z. Evercore suggested the upcoming HAELO results adjacent outpouring could supply a clearer accidental to reassess the company’s outlook.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is simply a clinical‑stage cistron editing institution processing curative treatments done successful vivo and engineered compartment therapy programs. Its pipeline includes NTLA‑2001 for ATTR amyloidosis and NTLA‑2002 for hereditary angioedema, alongside collaborations with AvenCell, Kyverna, ONK Therapeutics, and ReCode to beforehand CAR‑T, NK cell, and genomic medicine platforms targeting cancer, autoimmune disorders, and cystic fibrosis.

While we admit the imaginable of NTLA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.